Endoscopic eradication therapy (EET) is safe and effective in the management of Barrett’s esophagus (BE) related dysplasia and early adenocarcinoma. EET includes endoscopic resection of the visible lesions followed by ablation to eradicate the residual Barrett’s epithelium. Techniques available for endoscopic resection include cap-based endoscopic mucosal resection and endoscopic submucosal dissection. Ablative therapies such as RFA, cryoablation and APC are used for the eradication of dysplastic BE and to prevent progression to EAC. Complete remission of intestinal metaplasia is the goal of EET. Post-treatment endoscopic surveillance is recommended to detect recurrence of metaplasia/dysplasia, mostly at the gastroesophageal junction.
ShaheenNJFalkGWIyerPGGersonLB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30-51. doi:10.1038/ajg.2015.322
2.
DesaiTKKrishnanKSamalaN, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970-976. doi:10.1136/gutjnl-2011-300730
3.
KrishnamoorthiRMohanBPJayarajM, et al. Risk of progression in Barrett’s esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. doi:10.1016/j.gie.2019.07.037
4.
SinghSManickamPAminAV, et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(6):897-983.e3. doi:10.1016/j.gie.2014.01.009
5.
HarrisonMAllenJEGorrepatiVSLópez-JamarJMESharmaP. Management of Barrett’s esophagus with low-grade dysplasia. Dis Esophagus. 2018;31(4). doi:10.1093/dote/doy004
6.
CurversWLTen KateFJKrishnadathKK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523-1530. doi:10.1038/ajg.2010.171
7.
PhoaKNvan VilsterenFGWeustenBL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209-1217. doi:10.1001/jama.2014.2511
8.
QumseyaBJWaniSGendySHarnkeBBergmanJJWolfsenH. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112(6):849-865. doi:10.1038/ajg.2017.70
9.
SchölvinckDWvan der MeulenKBergmanJJGHMWeustenBLAM. Detection of lesions in dysplastic Barrett’s esophagus by community and expert endoscopists. Endoscopy. 2017;49(2):113-120. doi:10.1055/s-0042-118312
10.
PetersFPBrakenhoffKPCurversWL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc. 2008;67(4):604-609. doi:10.1016/j.gie.2007.08.039
11.
ShaheenNJSharmaPOverholtBF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277-2288. doi:10.1056/NEJMoa0808145
12.
DesaiMSaligramSGuptaN, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85(3):482-495.e4. doi:10.1016/j.gie.2016.09.022
13.
DunbarKBSpechlerSJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am J Gastroenterol. 2012;107(6):850-863. doi:10.1038/ajg.2012.78
14.
WuJPanYMWangTTGaoDJHuB. Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: a meta-analysis. Gastrointest Endosc. 2014;79(2):233-241.e2. doi:10.1016/j.gie.2013.08.005
15.
MannerHMayAPechO, et al. Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103(10):2589-2597. doi:10.1111/j.1572-0241.2008.02083.x
16.
PechOGossnerLMannerH, et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy. 2007;39(7):588-593. doi:10.1055/s-2007-966363
17.
PechOMayAMannerH, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146(3):652-660.e1. doi:10.1053/j.gastro.2013.11.006
18.
EllCMayAPechO, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc. 2007;65(1):3-10. doi:10.1016/j.gie.2006.04.033
19.
BehrensAMayAGossnerL, et al. Curative treatment for high-grade intraepithelial neoplasia in Barrett’s esophagus. Endoscopy. 2005;37(10):999-1005. doi:10.1055/s-2005-870352
20.
LarghiALightdaleCJRossAS, et al. Long-term follow-up of complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007;39(12):1086-1091. doi:10.1055/s-2007-966788
21.
GuoHMZhangXQChenMHuangSLZouXP. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol. 2014;20(18):5540-5547. doi:10.3748/wjg.v20.i18.5540
22.
TerheggenGHornEMViethM, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett’s neoplasia. Gut. 2017;66(5):783-793. doi:10.1136/gutjnl-2015-310126
23.
YangDZouFXiongSFordeJJWangYDraganovPV. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc. 2018;87(6):1383-1393. doi:10.1016/j.gie.2017.09.038
24.
IsomotoHYamaguchiNMinamiHNakaoK. Management of complications associated with endoscopic submucosal dissection/endoscopic mucosal resection for esophageal cancer. Dig Endosc. 2013;25(Suppl 1):29-38. doi:10.1111/j.1443-1661.2012.01388.x
25.
OrmanESLiNShaheenNJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245-1255. doi:10.1016/j.cgh.2013.03.039
26.
MohanBPKrishnamoorthiRPonnadaS, et al. Liquid nitrogen spray cryotherapy in treatment of Barrett’s esophagus, where do we stand? A systematic review and meta-analysis. Dis Esophagus. 2019;32(6):doy130. doi:10.1093/dote/doy130
27.
TariqREnslinSHayatMKaulV. Efficacy of cryotherapy as a primary endoscopic ablation modality for dysplastic Barrett’s esophagus and early esophageal neoplasia: a systematic review and meta-analysis. Cancer Control. 2020;27(1):1073274820976668. doi:10.1177/1073274820976668
28.
WesterveldDRNguyenKBanerjeeD, et al. Safety and effectiveness of balloon cryoablation for treatment of Barrett’s associated neoplasia: systematic review and meta-analysis. Endosc Int Open. 2020;8(2):E172-E178. doi:10.1055/a-1067-4520
29.
MannerHMayAKoutiIPechOViethMEllC. Efficacy and safety of Hybrid-APC for the ablation of Barrett’s esophagus. Surg Endosc. 2016;30(4):1364-1370. doi:10.1007/s00464-015-4336-1
30.
QumseyaBJWaniSDesaiM, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1086-1095. doi:10.1016/j.cgh.2016.04.001
31.
ShaheenNJGreenwaldBDPeeryAF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71(4):680-685. doi:10.1016/j.gie.2010.01.018
32.
GosainSMercerKTwaddellWSUradomoLGreenwaldBD. Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc. 2013;78(2):260-265. doi:10.1016/j.gie.2013.03.002
33.
RamayFHCuiQGreenwaldBD. Outcomes after liquid nitrogen spray cryotherapy in Barrett’s esophagus-associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc. 2017;86(4):626-632. doi:10.1016/j.gie.2017.02.006
34.
VisrodiaKZakkoLSinghSLeggettCLIyerPGWangKK. Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc. 2018;87(6):1396-1404.e1. doi:10.1016/j.gie.2018.02.021
35.
CantoMIShaheenNJAlmarioJAVoltaggioLMontgomeryELightdaleCJ. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc. 2018;88(3):438-446.e2. doi:10.1016/j.gie.2018.03.024
36.
CantoMITrindadeAJAbramsJ, et al. Multifocal cryoballoon ablation for eradication of Barrett’s esophagus-related neoplasia: a prospective multicenter clinical trial. Am J Gastroenterol. 2020;115(11):1879-1890. doi:10.14309/ajg.0000000000000822
37.
PeerallyMFBhandariPRagunathK, et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE). Gastrointest Endosc. 2019;89(4):680-689. doi:10.1016/j.gie.2018.07.031
38.
SawasTAlsawasMBazerbachiF, et al. Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett’s esophagus increases the risk of dysplasia recurrence: meta-analysis. Gastrointest Endosc. 2019;89(5):913-925.e6. doi:10.1016/j.gie.2018.11.035
39.
LuckettTAllamneniCCowleyKEickJGullickAPeterS. Length of Barrett’s segment predicts failure of eradication in radiofrequency ablation for Barrett’s esophagus: a retrospective cohort study. BMC Gastroenterol. 2018;18(1):67. doi:10.1186/s12876-018-0799-6
40.
KrishnanKPandolfinoJEKahrilasPJKeeferLBorisLKomanduriS. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143(3):576-581. doi:10.1053/j.gastro.2012.05.005
41.
ShimamuraYIwayaYKobayashiR, et al. Clinical and pathological predictors of failure of endoscopic therapy for Barrett’s related high-grade dysplasia and early esophageal adenocarcinoma. Surg Endosc. Published online September28, 2020. doi:10.1007/s00464-020-08037-x
42.
CodipillyDCDhaliwalLOberoiM, et al. Comparative outcomes of cap assisted endoscopic resection and endoscopic submucosal dissection in dysplastic Barrett’s esophagus. Clin Gastroenterol Hepatol. Published online November18, 2020. doi:10.1016/j.cgh.2020.11.017
43.
KrishnamoorthiRSinghSRagunathanKKatzkaDAWangKKIyerPG. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc. 2016;83(6):1090-1106.e3. doi:10.1016/j.gie.2016.02.009
44.
GuptaMIyerPGLutzkeL, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145(1):79-86.e1. doi:10.1053/j.gastro.2013.03.008
45.
TanMCKanthasamyKAYehAG, et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol. 2019;17(1):65-72.e5. doi:10.1016/j.cgh.2018.05.042
46.
SamiSSRavindranAKahnA, et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut. 2019;68(8):1379-1385. doi:10.1136/gutjnl-2018-317513
47.
SharmaPShaheenNJKatzkaDBergmanJJ. AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and/or early cancer: expert review. Gastroenterology. 2020;158(3):760-769. doi:10.1053/j.gastro.2019.09.051
